Document Detail

Oncolytic reovirus type 3 (Dearing) as a novel therapy in head and neck cancer.
MedLine Citation:
PMID:  23140488     Owner:  NLM     Status:  MEDLINE    
INTRODUCTION: Locally advanced head and neck cancer carries a poor prognosis, even with standard combination (surgery, radiotherapy, chemotherapy) treatment regimens. There is a pressing need for novel therapies with activity against this tumour type. Oncolytic reovirus type 3 (Dearing) is preferentially cytotoxic in tumour cells with an activated Ras signalling pathway and represents a promising novel therapy with relevance in head and neck cancer.
AREAS COVERED: In this review, we discuss the pre-clinical and clinical data that have underpinned the translational development of oncolytic reovirus thus far. In particular, we describe the iterative nature of the research programme through initial studies testing single-agent reovirus therapy and on to subsequent work in which reovirus has been combined with either radiotherapy or cytotoxic chemotherapy. We will trace the process by which oncolytic reovirus has reached Phase III evaluation in combination with carboplatin/paclitaxel in patients with platin-refractory, relapsed/metastatic head and neck cancer.
EXPERT OPINION: Reovirus is a self-amplifying, cancer-selective agent that offers huge potential advantages over standard chemotherapy, targeted small molecules or monoclonal antibodies. However, it is most likely that reovirus will show efficacy and be approved in combination with standard modalities (cytotoxic chemotherapy or radiotherapy) or other targeted agents, especially those that modulate signal transduction pathways. The next 5 years are critical for the development of oncolytic reovirus as an anti-cancer therapy and hinge on the ongoing Phase III trial in head and neck cancer and other Phase II programmes.
Joan N Kyula; Victoria Roulstone; Eleni M Karapanagiotou; Alan A Melcher; Kevin J Harrington
Related Documents :
24862138 - Treatment of cancer-associated thrombosis: perspectives on the use of novel oral antico...
20212228 - New strategies in the management of leptomeningeal metastases.
24523748 - Synthesis and in-vitro cytotoxicity assessment of n-(5-(benzylthio)-1,3,4- thiadiazol-2...
23242008 - Polyphenols as a chemopreventive agent in oral carcinogenesis: putative mechanisms of a...
17431228 - Novel perspectives for progesterone in hormone replacement therapy, with special refere...
12382188 - The molecular basis of radiosensitivity and chemosensitivity in the treatment of breast...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Expert opinion on biological therapy     Volume:  12     ISSN:  1744-7682     ISO Abbreviation:  Expert Opin Biol Ther     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-11-12     Completed Date:  2013-02-15     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  101125414     Medline TA:  Expert Opin Biol Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  1669-78     Citation Subset:  IM    
The Institute of Cancer Research, Targeted Therapy Team, Chester Beatty Laboratories, London, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Clinical Trials as Topic
Head and Neck Neoplasms / therapy*
Mammalian orthoreovirus 3*
Oncolytic Virotherapy*
Erratum In:
Expert Opin Biol Ther. 2013 Jan;13(1):147

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The tree alignment problem.
Next Document:  Gene expression profiling of macrophages: implications for an immunosuppressive effect of dissolucyt...